SG11201907276TA - Compositions of gallium (iii) complexes for oral administration - Google Patents
Compositions of gallium (iii) complexes for oral administrationInfo
- Publication number
- SG11201907276TA SG11201907276TA SG11201907276TA SG11201907276TA SG11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA SG 11201907276T A SG11201907276T A SG 11201907276TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gaq3
- lexi
- vancouver
- pharma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457712P | 2017-02-10 | 2017-02-10 | |
| PCT/IB2018/000213 WO2018146551A2 (en) | 2017-02-10 | 2018-02-09 | Compositions of gallium (iii) complexes for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907276TA true SG11201907276TA (en) | 2019-09-27 |
Family
ID=63106002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907276TA SG11201907276TA (en) | 2017-02-10 | 2018-02-09 | Compositions of gallium (iii) complexes for oral administration |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10548849B2 (ko) |
| EP (1) | EP3582778B1 (ko) |
| JP (1) | JP2020513030A (ko) |
| KR (1) | KR20190121784A (ko) |
| CN (1) | CN110381945A (ko) |
| AU (1) | AU2018218326A1 (ko) |
| BR (1) | BR112019016400A2 (ko) |
| CA (1) | CA3051545A1 (ko) |
| IL (1) | IL268379A (ko) |
| MX (1) | MX2019009510A (ko) |
| MY (1) | MY194485A (ko) |
| PH (1) | PH12019501868A1 (ko) |
| RU (1) | RU2019128191A (ko) |
| SG (1) | SG11201907276TA (ko) |
| WO (1) | WO2018146551A2 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019220282A1 (en) * | 2018-05-14 | 2019-11-21 | Capsugel Belgium Nv | Solid dosage forms with high active agent loading |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004951A (en) * | 1989-11-22 | 1999-12-21 | Bernstein; Lawrence Richard | Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual |
| WO2005058331A1 (en) * | 2003-12-17 | 2005-06-30 | Titan Pharmaceuticals, Inc. | Use of gallium to treat inflammatory arthritis |
| WO2007100382A2 (en) * | 2005-10-27 | 2007-09-07 | Bernstein Lawrence R | Orally administrable gallium compositions and method of use |
| EP1948159A4 (en) * | 2005-11-04 | 2011-10-12 | Genta Inc | PHARMACEUTICAL COMPOSITIONS OF GALLIUM AND METHODS |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| CN103002895A (zh) | 2010-02-12 | 2013-03-27 | 尼基制药公司 | 治疗血液癌症的方法 |
| CA2831206A1 (en) | 2010-04-23 | 2011-10-27 | Niiki Pharma Inc. | Method for treating pancreatic cancer |
| US20140127271A1 (en) * | 2012-04-11 | 2014-05-08 | Intezyne Technologies, Inc. | Block copolymers for stable micelles |
| TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
| JP6353061B2 (ja) * | 2013-09-25 | 2018-07-04 | ダウ グローバル テクノロジーズ エルエルシー | 有機液体希釈剤及び特定のヒドロキシアルキルメチルセルロースを含む組成物 |
-
2018
- 2018-02-09 WO PCT/IB2018/000213 patent/WO2018146551A2/en unknown
- 2018-02-09 CN CN201880011194.1A patent/CN110381945A/zh active Pending
- 2018-02-09 JP JP2019565072A patent/JP2020513030A/ja active Pending
- 2018-02-09 EP EP18750591.2A patent/EP3582778B1/en active Active
- 2018-02-09 AU AU2018218326A patent/AU2018218326A1/en not_active Abandoned
- 2018-02-09 MY MYPI2019004550A patent/MY194485A/en unknown
- 2018-02-09 US US15/893,396 patent/US10548849B2/en not_active Expired - Fee Related
- 2018-02-09 RU RU2019128191A patent/RU2019128191A/ru unknown
- 2018-02-09 MX MX2019009510A patent/MX2019009510A/es unknown
- 2018-02-09 CA CA3051545A patent/CA3051545A1/en active Pending
- 2018-02-09 KR KR1020197026170A patent/KR20190121784A/ko not_active Application Discontinuation
- 2018-02-09 SG SG11201907276TA patent/SG11201907276TA/en unknown
- 2018-02-09 BR BR112019016400A patent/BR112019016400A2/pt not_active Application Discontinuation
-
2019
- 2019-07-31 IL IL268379A patent/IL268379A/en unknown
- 2019-08-13 PH PH12019501868A patent/PH12019501868A1/en unknown
- 2019-10-08 US US16/596,603 patent/US10933021B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009510A (es) | 2019-11-25 |
| BR112019016400A2 (pt) | 2020-04-07 |
| PH12019501868A1 (en) | 2020-07-06 |
| AU2018218326A1 (en) | 2019-08-22 |
| US20180228734A1 (en) | 2018-08-16 |
| US20200038334A1 (en) | 2020-02-06 |
| EP3582778B1 (en) | 2022-10-05 |
| WO2018146551A4 (en) | 2018-11-22 |
| WO2018146551A3 (en) | 2018-10-04 |
| JP2020513030A (ja) | 2020-04-30 |
| IL268379A (en) | 2019-09-26 |
| EP3582778A2 (en) | 2019-12-25 |
| US10933021B2 (en) | 2021-03-02 |
| CN110381945A (zh) | 2019-10-25 |
| WO2018146551A2 (en) | 2018-08-16 |
| CA3051545A1 (en) | 2018-08-16 |
| MY194485A (en) | 2022-11-30 |
| EP3582778A4 (en) | 2020-12-23 |
| KR20190121784A (ko) | 2019-10-28 |
| US10548849B2 (en) | 2020-02-04 |
| RU2019128191A3 (ko) | 2021-05-31 |
| RU2019128191A (ru) | 2021-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
| SG11201908171TA (en) | Compounds and compositions for treating hematological disorders | |
| SG11201809688RA (en) | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201805001UA (en) | Method of treating influenza a |